The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...
Citius Oncology, Inc. ("Citius Oncology") , an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") , today announced positive ...
A case study shows how sickle cell retinopathy may be the first clinical manifestation of underlying hemoglobinopathy.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage clinical progress for its lead retinal candidate DURAVYU and ...
Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...
Explore the top 15 building products for February 2026—from high-performance curtainwall systems and low-E glass to formaldehyde-free insulation and structural data center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results